Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs)
$69.27
neg -0.33
-0.47%
Today's Range: 69.18 - 69.96 | BMRN Avg Daily Volume: 1,030,700
Last Update: 09/19/14 - 11:41 AM EDT
Volume: 517,906
YTD Performance: 0.00%
Open: $69.75
Previous Close: $69.60
52 Week Range: $55.04 - $84.25
Oustanding Shares: 147,116,873
Market Cap: 10,034,841,907
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 10 9
Moderate Buy 0 0 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.67 1.67 1.67 1.71
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
0.00 0.00 28.82
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 9.50 0.46 0.13
Net Income 0.00 -1.86 0.00
EPS 0.00 -1.64 0.00
Earnings for BMRN:
EBITDA -0.10B
Revenue 0.55B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $-0.19 $-0.62 $-1.30 $-1.10
Number of Analysts 9 9 11 10
High Estimate $0.03 $-0.45 $-0.96 $-0.71
Low Estimate $-0.90 $-0.73 $-1.97 $-1.80
Prior Year $-0.38 $-0.27 $-0.76 $-1.30
Growth Rate (Year over Year) 50.58% -129.22% -70.93% 15.17%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bob Byrne

 | Jul 9, 2014 | 7:30 AM EDT

The focus is on all things momentum.

By

Bob Byrne

 | Jun 23, 2014 | 7:30 AM EDT

For Es, I believe the odds will remain in the bulls' favor.

By

Bob Byrne

 | Jun 19, 2014 | 7:30 AM EDT

No reason to be bearish on the SPY.

By

Bob Byrne

 | Jun 12, 2014 | 7:30 AM EDT

Don't sweat Wednesday's dip in the SPY.

bullishBiomarin upgraded at Credit Suisse

Jun 9, 2014 | 8:20 AM EDT

BMRN was upgraded from Neutral to Outperform, Credit Suisse said. $73 price target. Stock has pulled back to an attractive entry point. 

By

Bob Byrne

 | Jun 5, 2014 | 7:30 AM EDT

The $193 level on the SPY will be key today.

By

Bob Byrne

 | May 29, 2014 | 7:30 AM EDT

Thursday's SPY trade plan will involve fading the edges,

By

Timothy Collins

 | May 19, 2014 | 2:00 PM EDT

BioMarin and Goldcorp couldn't be more different -- and similar.

bullishBioMarin Pharmaceutical price target bumped up at UBS

May 2, 2014 | 8:12 AM EDT

BMRN raised its number, UBS said. Driven by Vimizin launch. $74 price target and Buy rating. 

By

Jim Cramer

 | Apr 16, 2014 | 11:45 AM EDT

Algos think faster and react faster than humans can.

The action in CAG has been very volatile this week. On Wednesday the stock was drag...
the longer the wait for the baba opening the more the emotions are in play...that tactic f...
The ghost of William Wallace can get back to sleep now that Scotland is staying in the UK....
TIBCO reported disappointing revenue and earnings last night and lowered their next quarte...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.